Tier 2 — strong

Quercetin in the treatment of dyslipidemia

Emir Talirevic, Sehovic Jelena
Medicinski arhiv 2012 66(2):87

Bibliography

PubMed
PMID 22486135
DOI
10.5455/medarh.2012.66.87-88
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignReported double-blind randomized dyslipidemia trial
ModelHuman intervention research
Sample400 adults, reported as 200 per arm
InterventionQuercetin intervention; dose not stated in the indexed abstract
Duration2 months
EndpointsLipid measurements

What the study showed, in plain terms

Published in 2012, this source examined cardiovascular and metabolic health. Design: Reported double-blind randomized dyslipidemia trial. Sample/model: 400 adults, reported as 200 per arm. The exposure or intervention was Quercetin intervention; dose not stated in the indexed abstract. Follow-up or treatment period: 2 months.

The abstract reports improved lipid values in the intervention group.

The abstract omits the quercetin dose and adequate final between-group results. Reporting limitations prevent a firm estimate of treatment effect or comparison with established lipid therapy.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The abstract reports improved lipid values in the intervention group.
  • The recorded outcome domains were Lipid measurements.
  • The result applies to the tested exposure: Quercetin intervention; dose not stated in the indexed abstract; 2 months.

What this study can and cannot tell us

  • The abstract omits the quercetin dose and adequate final between-group results. Reporting limitations prevent a firm estimate of treatment effect or comparison with established lipid therapy.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 2
Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension
Valentyna Volodymyrivna Chopyak et al. · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2025
Tier 2
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN
Maryana I Prokosa et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2022
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology